News

A Phase 2 clinical trial of a new optimized formulation of adrulipase, a yeast-derived enzyme for treating exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis (CF), is about to start. First Wave BioPharma, its developer, anticipates patient screening will start early this month, with top-line results expected…

At least three months of using the triple combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly increased glucose tolerance — reflecting better control of blood sugar levels — in adults with cystic fibrosis (CF), a small study found. Production of insulin, the hormone that helps clear glucose from the bloodstream, wasn’t…

Among children with cystic fibrosis (CF), bone health tends to become worse with older age — and poor bone health in CF is linked to less activity of nearby muscle — a new study suggests. The findings imply that promoting physical activity for children with CF could help to…

Lipid levels in human saliva were found to be significantly linked to complications related to cystic fibrosis (CF) — such as poor lung function — and may act as a biomarker for assessing disease activity, according to a new study. These findings suggest that a non-invasive assessment of salivary…

CFTR gene mutations — the cause of cystic fibrosis (CF) — significantly reduce the cell entry and replication of SARS-CoV-2, the virus responsible for COVID-19, a new study reports. This protective effect was due to the link between the CFTR protein channel and angiotensin-converting enzyme 2 (ACE-2), a protein…

CFTR modulators, approved therapies to treat cystic fibrosis (CF), showed antibacterial activity and enhanced the efficacy of some antibiotics against bacterial species commonly found in CF airways, according to a new study. “Additive effects or synergies were observed between the CFTR modulators and antibiotics against [two common] species” of…

Having cystic fibrosis (CF) can put a tremendous financial strain on patients: In the U.K., the typical family affected by the genetic disease will lose more than £6,500 (about $8,000) every year as a consequence. That’s according to a new report, “The Financial Costs of Cystic…

People with cystic fibrosis (CF) and advanced lung disease who have bacterial communities dominated by just one type of bacteria have a higher risk of lung transplant or death than those with more diverse communities, a study reports. The risk of needing a lung transplant or death was increased…

A higher body mass index (BMI) and recent exposure to certain antibiotics are risk factors for asymptomatic intestinal colonization with Clostridioides difficile in children with cystic fibrosis (CF), a new study suggests. The study, “Prevalence, Risk Factors, and Sequelae of Asymptomatic Clostridioides difficile Colonization in Children with Cystic…

Up to four years of treatment with Symdeko (tezacaftor/izacaftor) is safe and effective in people with cystic fibrosis (CF) with one or two copies of F508del, a common CF-causing mutation. That’s according to new long-term data from an open-label Phase 3 trial that tested the approved CF therapy…